Literature DB >> 7780258

Automatic needle insertion diminishes pain during growth hormone injection.

K M Main1, J T Jørgensen, N T Hertel, S Jensen, L Jakobsen.   

Abstract

Non-compliance in children receiving growth hormone (GH) treatment is often caused by pain on injection and difficulties in administration of GH. It has been suggested that automatic needle insertion diminishes pain perception. We quantitatively measured pain intensity on injection with two prototype pens for GH administration, providing either manual or automatic sc needle insertion, using a combined visual analogue/facial scale and a five-item scale in 18 children. With the automatic pen there was a significantly lower maximum pain score compared with the manual pen (median 28.5 versus 52.0 mm) as well as a lower mean pain score (mean 13.7 versus 23.5 mm). The five-item scale revealed that automatic needle insertion was significantly less painful than manual insertion and 13 patients chose to continue treatment with the automatic pen. In conclusion, pain during GH injection can be significantly diminished by automatic needle insertion, which may improve compliance in long-term GH treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780258     DOI: 10.1111/j.1651-2227.1995.tb13638.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.

Authors:  M L Drent; S Jakobsdottir; J A E van Wijk; W Oostdijk; J M Wit
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

2.  Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers.

Authors:  Cecile Berteau; Florence Schwarzenbach; Yves Donazzolo; Mathilde Latreille; Julie Berube; Herve Abry; Joël Cotten; Celine Feger; Philippe E Laurent
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

3.  Non-compliance with growth hormone treatment in children is common and impairs linear growth.

Authors:  Wayne S Cutfield; José G B Derraik; Alistair J Gunn; Kyle Reid; Theresa Delany; Elizabeth Robinson; Paul L Hofman
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

4.  Defining the ideal injection techniques when using 5-mm needles in children and adults.

Authors:  Paul Leslie Hofman; José Guilherme Behrensdorf Derraik; Teresa Elizabeth Pinto; Sheryl Tregurtha; Ann Faherty; Jane Michele Peart; Paul Leslie Drury; Elizabeth Robinson; Ramin Tehranchi; Morten Donsmark; Wayne Stephen Cutfield
Journal:  Diabetes Care       Date:  2010-06-28       Impact factor: 19.112

5.  Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.

Authors:  Anita Hokken-Koelega; Alexandra Keller; Viatcheslav Rakov; Stefan Kipper; Jovanna Dahlgren
Journal:  ISRN Endocrinol       Date:  2011-09-20

6.  Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatment.

Authors:  Hyun Wook Chae; Il-Tae Hwang; Ji-Eun Lee; Cheol Hwan So; Young-Jun Rhie; Jung Sub Lim; Eun Byul Kwon; Kyung Hee Yi; Eun Young Kim; Chae-Ku Jo; Kye Shik Shim; Ha-Yeong Gil; Min-Jeong Seong; Chung Mo Nam; Ji-Su Moon; Jin Soon Hwang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-07       Impact factor: 6.055

7.  Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis.

Authors:  Jaime A Pachon; Alan J Kivitz; Kay-Uwe Heuer; Uwe Pichlmeier
Journal:  SAGE Open Med       Date:  2014-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.